newsfilter
← Latest News
PR Newswire·

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...